Co-delivery of doxorubicin and RNA using pH-sensitive poly (β-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer

Biomaterials

Volumn 35, Issue 23, 2014, Pages 6047-6059

  Tang, Shan ^a   Yin, Qi ^a   Zhang, Zhiwen ^a   Gu, Wangwen ^a   Chen, Lingli ^a   Yu, Haijun ^a   Huang, Yongzhuo ^a   Chen, Xianzhi ^a   Xu, Minghua ^a   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Co delivery; Doxorubicin; Multidrug resistance; PH sensitive; Poly ( amino ester); RNA interference

Indexed keywords

CELL DEATH; DISEASES; DRUG THERAPY; ESTERIFICATION; ESTERS; NANOPARTICLES; PHARMACODYNAMICS; RNA; STRESS ANALYSIS; SYNTHESIS (CHEMICAL); TUMORS;

AMINO ESTERS; CO DELIVERIES; DOXORUBICIN; MULTIDRUG RESISTANCE; PH SENSITIVE; RNA INTERFERENCE;

LOADING;

DOXORUBICIN; NANOPARTICLE; POLY[(1,4 BUTANEDIOL)DIACRYLATE BETA 5 HYDROXYAMYLAMINE]; POLY[(1,4 BUTANEDIOL)DIACRYLATE BETA 5 POLYETHYLENIMINE]; SHORT HAIRPIN RNA; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; NANOCAPSULE; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SYNTHESIS; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG RESISTANCE; GENE THERAPY; GENETICS; MCF 7 CELL LINE; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC THERAPY; HUMANS; HYDROGEN-ION CONCENTRATION; MCF-7 CELLS; MICE; MICE, INBRED BALB C; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; RNA; RNA INTERFERENCE; TREATMENT OUTCOME;

EID: 84900026113     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.025     Document Type: Article

References (30)

1. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
2. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
3. Peer D., Karp J.M., Hong S., FaroKHzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
4. Nie S.M., Xing Y., Kim G.J., Simons J.W. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007, 9:257-288.
5. Yague E., Higgins C.F., Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther 2004, 11:1170-1174.
6. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 2005, 12:217-227.
7. Duan X., Xiao J., Yin Q., Zhang Z., Yu H., Mao S., et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 2013, 7:5858-5869.
8. Liu S.H., Guo Y.B., Huang R.Q., Li J.F., Huang S.X., Kuang Y.Y., et al. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials 2012, 33:4907-4916.
9. Wang Y., Gao S.J., Ye W.H., Yoon H.S., Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
10. Chen A.M., Zhang M., Wei D.G., Stueber D., Taratula O., Minko T., et al. Co-delivery of doxorubicin and bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
11. Vaidya A., Sun Y.G., Feng Y., Emerson L., Jeong E.K., Lu Z.R. Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate. Pharm Res 2008, 25:2002-2011.
12. Zugates G.T., Peng W.D., Zumbuehl A., Jhunjhunwala S., Huang Y.H., Langer R., et al. Rapid optimization of gene delivery by parallel end-modification of poly(beta-amino ester)s. Mol Ther 2007, 15:1306-1312.
13. Green J.J., Langer R., Anderson D.G. Acombinatorial polymer library approach yields insight into nonviral gene delivery. Acc Chem Res 2008, 41:749-759.
14. Zugates G.T., Tedford N.C., Zumbuehl A., Jhunjhunwala S., Kang C.S., Griffith L.G., et al. Gene delivery properties of end-modified poly(beta-amino ester)s. Bioconjug Chem 2007, 18:1887-1896.
15. Gu J., Wang X., Jiang X., Chen Y., Chen L., Fang X., et al. Self-assembled carboxymethyl poly (L-histidine) coated poly (beta-amino ester)/DNA complexes for gene transfection. Biomaterials 2012, 33:644-658.
16. Yang F., Green J.J., Dinio T., Keung L., Cho S.W., Park H., et al. Gene delivery to human adult and embryonic cell-derived stem cells using biodegradable nanoparticulate polymeric vectors. Gene Ther 2009, 16:533-546.
17. Shen J.A., Yin Q., Chen L.L., Zhang Z.W., Li Y.P. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 2012, 33:8613-8624.
18. Green J.J., Chiu E., Leshchiner E.S., Shi J., Langer R., Anderson D.G. Electrostatic ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary cells. Nano Lett 2007, 7:874-879.
19. Hashimoto M., Morimoto M., Saimoto H., Shigemasa Y., Sato T. Lactosylated chitosan for DNA delivery into hepatocytes: the effect of lactosylation on the physicochemical properties and intracellular trafficking of pDNA/chitosan complexes. Bioconjug Chem 2006, 17:309-316.
20. Ryu J.H., Chacko R.T., Jiwpanich S., Bickerton S., Babu R.P., Thayumanavan S. Self-cross-linked polymer nanogels: a versatile nanoscopic drug delivery platform. JAm Chem Soc 2010, 132:17227-17235.
21. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. JControl Release 2010, 148:135-146.
22. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002, 54:631-651.
23. Verma A., Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 6:12-21.
24. Vijayaraghavalu S., Peetla C., Lu S., Labhasetwar V. Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions. Mol Pharmacol 2012, 9:2730-2742.
25. Regev R., Eytan G.D. Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem Pharmacol 1997, 54:1151-1158.
26. Regev R., Yeheskely-Hayon D., Katzir H., Eytan G.D. Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism. Biochem Pharmacol 2005, 70:161-169.
27. Douglas K.L., Piccirillo C.A., Tabrizian M. Cell line-dependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors. Eur J Pharm Biopharm 2008, 68:676-687.
28. Jha K., Shukla M., Pandey M. Survivin expression and targeting in breast cancer. Surg Oncol 2012, 21:125-131.
29. Yin Q., Shen J.A., Chen L.L., Zhang Z.W., Gu W.W., Li Y.P. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(beta-amino esters). Biomaterials 2012, 33:6495-6506.
30. Notarbartolo M., Cervello M., Dusonchet L., Cusimano A., D'Alessandro N. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of p-glycoprotein, fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett 2002, 180:91-101.